You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

potentially resectable

Showing 1 - 25 of 6,989
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)

Not yet recruiting
  • Potentially Resectable Hepatocellular Carcinoma
  • (no location specified)
Nov 16, 2023

Hepatocellular Carcinoma Trial in Guangzhou (SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 9, 2023

Biliary Tract Tumors Trial (Total Neoadjuvant Treatment)

Not yet recruiting
  • Biliary Tract Neoplasms
  • Total Neoadjuvant Treatment
  • (no location specified)
Sep 7, 2023

NSCLC Trial in Beijing

Recruiting
  • NSCLC
    • Beijing, China
      Yuyan Wang
    Oct 10, 2023

    Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)

    Not yet recruiting
    • Pancreatic Cancer
    • Baltimore, Maryland
      SKCCC Johns Hopkins
    Aug 16, 2023

    Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)

    Not yet recruiting
    • Cholangiocarcinoma
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 21, 2023

    Pancreatic Carcinoma Trial in Nanjing (Toripalimab, Gemcitabine, Nab paclitaxel)

    Not yet recruiting
    • Pancreatic Carcinoma
    • Nanjing, Jiangsu, China
      The Affiliated Nanjing Drum Tower Hospital of Nanjing University
    Oct 6, 2023

    Stage III NSCLC Trial (Toripalimab, JS004, Pemetrexed)

    Not yet recruiting
    • Stage III Non-small Cell Lung Cancer
    • (no location specified)
    Jun 3, 2023

    Pancreatic Carcinoma Trial in Nanjing (Tislelizumab, Gemcitabine, Nab paclitaxel)

    Recruiting
    • Pancreatic Carcinoma
    • Nanjing, Jiangsu, China
      The Affiliated Nanjing Drum Tower Hospital of Nanjing University
    Dec 1, 2022

    Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 13, 2022

    Hepatocellular Carcinoma, Chemo Effect, Chemotherapeutic Toxicity Trial in Guangzhou (Oxaliplatin,calcium folinic acid,

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
    • +4 more
    • Guangzhou, Guangdong, China
      SUN Yat-sen University Cancer Center
    Sep 11, 2023

    Esophageal Squamous Cell Carcinoma Trial in Nanjing (Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1)

    Active, not recruiting
    • Esophageal Squamous Cell Carcinoma
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital with Nanjing Medical University
    Jul 16, 2022

    Pembrolizumab Combined With Double Platinum Based Chemotherapy

    Recruiting
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Feb 28, 2022

      Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

      Recruiting
      • Lung Adenocarcinoma Stage III
      • EGFR Gene Mutation
      • Shang'ai, Shanghai, China
        Shanghai Pulmonary Hospital
      Mar 27, 2022

      Gastroesophageal Junction Adenocarcinoma Trial in Shijiazhuang (Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent

      Completed
      • Gastroesophageal Junction Adenocarcinoma
      • Oxaliplatin; Capecitabine
      • Oxaliplatin; Capecitabine; concurrent radiotherapy
      • Shijiazhuang, Hebei, China
        Department of General Surgery
      Feb 4, 2022

      Mesothelioma Trial in Durham, Houston (Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemo plus

      Not yet recruiting
      • Mesothelioma
      • Durvalumab / tremelimumab
      • Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
      • Durham, North Carolina
      • +1 more
      Jul 5, 2023

      Hepatocellular Carcinoma Trial in Baltimore (Nivolumab, Relatlimab)

      Recruiting
      • Hepatocellular Carcinoma
      • Baltimore, Maryland
        Sidney Kimmel Comprehensive Cancer Center
      Mar 3, 2022

      Potentially Resectable Locally Advanced Malignant Tumors of Biliary System Trial (Tislelizumab)

      Not yet recruiting
      • Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
      • (no location specified)
      Sep 6, 2021

      Biliary Tract Cancer, PD-1 Antibody, Gemox Trial in Shanghai (PD-1+Lenvatinib+GEMOX)

      Recruiting
      • Biliary Tract Cancer
      • +3 more
      • Shanghai, China
        Zhongshan hospital
      Dec 11, 2021

      Cholangiocarcinoma Trial in Khon Kaen (mFOLFOXIRI)

      Recruiting
      • Cholangiocarcinoma
      • Khon Kaen, Thailand
        Jarin Chindaprasirt
      Aug 31, 2021

      Advanced Non Small Cell Lung Cancer Trial in Changsha (Toripalimab combination with platinum-containing dual-drug chemo)

      Recruiting
      • Advanced Non Small Cell Lung Cancer
      • Toripalimab combination with platinum-containing dual-drug chemotherapy
      • Changsha, Hunan, China
        Hunan Provincal Tumor Hospital
      Dec 28, 2021

      Potentially Resection, Hepatocellular Carcinoma Trial in Guangzhou (TACE-HAIC, HAIC)

      Recruiting
      • Potentially Resection
      • Hepatocellular Carcinoma
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Sep 20, 2021

      Stage III NSCLC Trial in Chengdu (Durvalumab, nanoparticle albumin bound paclitaxel, low dose radiation therapy)

      Recruiting
      • Stage III Non-small Cell Lung Cancer
      • Chengdu, Sichuan, China
        Sichuan Cancer Hospital
      Dec 2, 2021

      Toxicity, Drug Trial in Hefei (neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery)

      Recruiting
      • Toxicity, Drug
      • neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
      • Hefei, Anhui, China
        Anhui Provicial Hospital
      May 1, 2022

      Hepatocellular Carcinoma Trial in Shanghai (Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE)

      Enrolling by invitation
      • Hepatocellular Carcinoma
      • Lenvatinib 4 MG Oral Capsule [Lenvima]
      • +2 more
      • Shanghai, Shanghai, China
        Fudan University Zhongshan Hospital
      Sep 23, 2021